

7 October 2026

The Manager
Company Announcements Office
Australian Securities Exchange Limited
20 Bridge Street
Sydney NSW 2000

cyclopharm



cyclomedica technegas

Cyclopharm Ltd ABN 74 116 931 250
Unit 4, 1 The Crescent Kingsgrove NSW 2208 Australia T 61
2 9541 0411
F 61 2 9543 0960
www.cyclopharm.com.au

Chinese medical societies name Technegas® preferred ventilation agent, extending global consensus across the US, Europe, ANZ and China

Highlights

- Seven leading Chinese medical bodies have jointly published an expert consensus recommending Technegas® as the preferred ventilation agent for lung imaging in pulmonary embolism (PE)¹
- The Technegas® recommendation was agreed unanimously by working group members
- The multidisciplinary consensus was led by the Chinese Thoracic Society of the Chinese Medical Association, and included pulmonary vascular, pulmonary hypertension and nuclear medicine bodies, carrying the voice of physicians who order Technegas® imaging, as well as those who perform it
- It follows joint US and international guidelines released in July 2026 which named Technegas® “generally preferred when available”
- Clinical leadership in the US, Europe, Australia, NZ, with China now independently reaching the same conclusion
- Technegas® existing footprint extends to most provinces across China, where the nuclear medicine sector is expanding rapidly, supported by theranostics and national policy
- The consensus recognises lung V/Q imaging for screening, follow-up and treatment response in PE and chronic thromboembolic pulmonary hypertension (CTEPH)

Sydney, October 7, 2026: Cyclopharm (ASX: CYC) is pleased to announce publication in China of *Expert consensus on the operational protocol for radionuclide pulmonary ventilation/perfusion scintigraphy of pulmonary thromboembolism (Consensus)* in the October 2026 issue of the *Chinese Journal of Tuberculosis and Respiratory Diseases*, a peer-reviewed journal of the Chinese Medical Association.

The first of the Consensus’s ten recommendations is unambiguous: “For ventilation imaging, ^{99m}Tc-Technegas is recommended as the preferred radiopharmaceutical.” The alternative agent, DTPA aerosol, is to be used only if Technegas® is unavailable. The recommendation was reached unanimously.

The Consensus was published after a survey of nuclear medicine departments across multiple Chinese hospitals, which found that practice varied in how lung scans were ordered and that interpretation depended heavily on specialist expertise. Its purpose is to standardise how the scan is performed and reported across China.

A multidisciplinary endorsement

The Consensus was issued jointly by the:

- Chinese Thoracic Society of the Chinese Medical Association
- Chinese Association of Chest Physicians
- National Collaborative Group for Prevention and Treatment of Pulmonary Embolism and Pulmonary Vascular Diseases
- Expert Committee of the National Project of Standardized Diagnosis and Treatment of Pulmonary Hypertension
- Expert Committee of Pulmonary Embolism and Pulmonary Vascular Diseases of the National Center for Respiratory Medicine
- Cardiopulmonary Vascular Group of the Nuclear Medicine Branch, Beijing Medical Association; and
- Nuclear Medicine Physicians Branch of the Chinese Medical Doctor Association

¹ Chinese Thoracic Society, Chinese Medical Association; Chinese Association of Chest Physicians; et al. Expert consensus on the operational protocol for radionuclide pulmonary ventilation/perfusion scintigraphy of pulmonary thromboembolism. *Zhonghua Jie He He Hu Xi Za Zhi* (Chinese Journal of Tuberculosis and Respiratory Diseases) 2026;49(10):1072-1081. doi:10.3760/cma.j.cn112147-20260602-00327

This joint endorsement is significant because PE is diagnosed and managed by a team of respiratory physicians, emergency and critical care physicians, cardiologists, radiologists and nuclear medicine physicians. This Consensus brings these disciplines together. It is led by respiratory and pulmonary vascular medicine, the specialists who suspect the clot, order the scan and treat the patient, working alongside nuclear medicine, the specialty that performs and reports it. Demand for a lung scan begins with the referring physician, and hospital adoption decisions are made by committees drawn from all of these disciplines. In China, Technegas® now has the endorsement of them all.

A global consensus

In less than three months, the clinical leadership of the world's major healthcare systems has independently arrived at the same position:

- **United States, Europe, Australia and New Zealand (July 2026):** SNMMI, EANM, ACNM and ANZSNM: Technegas® “generally preferred when available”
- **China (October 2026):** Chinese Thoracic Society and six partner bodies: Technegas® “recommended as the preferred radiopharmaceutical”, with 100% consensus

These positions on Technegas® were developed by different societies, under different processes, for different healthcare systems. They agree and, departing from the usual brand-neutral approach, both name Technegas® as the agent.

Beyond the initial diagnosis

Consistent with the guidelines announced in July and Cyclopharm's Beyond PE strategy, the Consensus recognises lung V/Q imaging not only for diagnosing PE but for screening, follow-up and assessing response to treatment in PE and CTEPH, including after balloon pulmonary angioplasty and pulmonary endarterectomy. It also sets out a V/Q protocol for pregnant women with suspected PE.

A growing nuclear medicine market in China

The Consensus comes as nuclear medicine in China is expanding rapidly, driven in part by advances in theranostics. The Chinese Society of Nuclear Medicine's 2024 national survey² reported 1,237 nuclear medicine departments, of which 787 offer SPECT imaging, the technique used for Technegas® lung scans. Together they performed more than 2.7 million SPECT scans in 2023. Since 2019, PET installations have risen 81%, PET/CT examinations 63% and the nuclear medicine workforce 25%. Under the Government's *Medical Isotope Development Plan (2021–2035)*, it is expected that China will roughly double the scale of nuclear medicine by 2035, extending departments to all high-grade hospitals and to every county.³

Cyclopharm's Managing Director and CEO, James McBrayer, said: “China's leading respiratory, pulmonary vascular and nuclear medicine bodies reviewed their own clinical experience, surveyed hospitals across China, and unanimously named Technegas® the preferred ventilation agent. That is a powerful statement from the physicians who manage these patients every day. Working independently, in a different healthcare system, they reached the same conclusion as the leading societies of the US, Europe and ANZ. When experts on both sides of the world look at the evidence separately and arrive at the same answer, it speaks to the clinical advantages of Technegas® itself.

“PE is a multidisciplinary disease. When the physicians who order the scan and the physicians who perform it agree, across four continents, that is no longer a regional preference. It is a global standard of care, and it is written in the profession's own words, not ours.”

This ASX announcement was authorised for release by James McBrayer, Managing Director, CEO and Company Secretary

For further information: James McBrayer, Managing Director, CEO and Company Secretary, Cyclopharm Limited – T: +61 (02) 9541 0411

Cyclopharm Limited

Cyclopharm is an ASX-listed radiopharmaceutical company servicing the global medical community. The Company's mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes. Cyclopharm achieves this objective primarily through the provision of its core radiopharmaceutical product, Technegas, used in functional lung ventilation imaging.

Technegas

The Technegas technology is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using dried Technetium-99m in a carbon crucible, micro-furnaced for a few seconds at around 2,700 °C. The resultant gas-like substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for evaluating functional lung ventilation. Historically used in the diagnosis of pulmonary embolism, Technegas, together with advancements in complementary technology, multimodality imaging, and analytical software, is being investigated and applied in other disease states, including COPD, asthma, pulmonary hypertension, and certain interventional applications, such as lobectomies in lung cancer and lung volume reduction surgery.

In the United States, Technegas® is indicated for the visualization of pulmonary ventilation and for the evaluation of pulmonary embolism when paired with perfusion imaging, in adults and paediatric patients aged 6 years and older. Please refer to the full US Prescribing Information for approved uses, important safety information and radiation dosimetry.

² Wang J, Lan X, Shi H, Li S. A Brief Report on the Results of the 2024 National Survey of Nuclear Medicine Conducted by the Chinese Society of Nuclear Medicine. *J Nucl Med* 2025;66(5):684-685. doi:10.2967/jnumed.124.269044

³ Yang W, Kang F, Chen Y, Zhu Z, Wang F, Qin C, Du J, Lan X, Wang J. Landscape of Nuclear Medicine in China and Its Progress on Theranostics. *J Nucl Med* 2024;65(Suppl 1):29S-37S. doi:10.2967/jnumed.123.266968